CHJTF:OTC-CSPC Pharmaceutical Group Ltd (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.83

Change

0.00 (0.00)%

Market Cap

USD 9.62B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

-12.79 (-1.56%)

USD 813.31B
NVO Novo Nordisk A/S

-2.22 (-1.98%)

USD 513.37B
JNJ Johnson & Johnson

-1.89 (-1.18%)

USD 399.33B
ABBV AbbVie Inc

-3.08 (-1.51%)

USD 359.54B
PFE Pfizer Inc

-0.33 (-1.17%)

USD 163.54B
BMY Bristol-Myers Squibb Company

+1.13 (+2.08%)

USD 112.46B
OGN Organon & Co

-1.15 (-6.36%)

USD 4.84B
NVS Novartis AG ADR

+1.17 (+1.07%)

N/A
GSK GlaxoSmithKline PLC ADR

+0.09 (+0.24%)

N/A
MRK Merck & Company Inc

-0.01 (-0.01%)

N/A

ETFs Containing CHJTF

KURE KraneShares MSCI All Chin.. 0.00 % 0.79 %

+0.20 (+1.35%)

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.75% 64% D 45% F
Dividend Return -5.59% 100% F 78% C+
Total Return -1.84% 55% F 33% F
Trailing 12 Months  
Capital Gain 15.28% 73% C 54% F
Dividend Return -6.21% 100% F 76% C+
Total Return 9.07% 73% C 43% F
Trailing 5 Years  
Capital Gain -67.45% 20% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.45% 20% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -19.25% 9% A- 13% F
Dividend Return -17.75% 12% F 14% F
Total Return 1.50% 35% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 22.16% 55% F 83% B
Risk Adjusted Return -80.11% 12% F 7% C-
Market Capitalization 9.62B 25% F 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector